Navigation Links
Updated Pictures of CEL-SCI Manufacturing Facility Available Online
Date:12/3/2008

VIENNA, Va., Dec. 3 /PRNewswire-FirstCall/ -- In response to numerous shareholder inquiries, CEL-SCI Corporation (NYSE Alternext US: CVM) announced today that it has added updated pictures of it new manufacturing facility to its website. The pictures can be accessed through CEL-SCI's homepage (http://www.cel-sci.com) by clicking on the link "Updated Pictures of Manufacturing Facility" in the special highlights section.

CEL-SCI is developing its cancer product Multikine(R) for approval as a first line indication in head and neck cancer. The manufacturing facility was built to supply the upcoming and FDA cleared Phase III clinical trial, as well as commercial sale, of Multikine as a first line indication in treatment naive head and neck cancer patients. Head and neck cancer is one of the world's biggest cancers affecting about 650,000 people per annum worldwide.

CEL-SCI already has two partners who will participate in the Phase III trial: Teva Pharmaceuticals and Orient Europharma of Taiwan. Discussions with other potential partners are ongoing.

In Phase II clinical trials Multikine was shown to be safe and well-tolerated, eliminate all of the tumor in 12% of the patients and to improve the patients' overall survival by 33% at a median of three and a half years following surgery.

CEL-SCI has operations in Vienna, Virginia and Baltimore, Maryland. CEL-SCI's other products, which are currently in pre-clinical stage, have shown protection against a number of diseases in animal tests and are being tested against diseases associated with bio-defense. Most recently CEL-SCI announced that its newly discovered rheumatoid arthritis vaccine showed very promising results in animal tests.


'/>"/>
SOURCE CEL-SCI Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. StollerUSA Launches Updated Web site For Growers and Farmers
2. Updated Online Tutorials for DBTSS, Pfam and PDB
3. Nuvelo Reports First Quarter 2008 Financial Results and Updated Outlook for 2008
4. Atherotech VAP Cholesterol Test Meets Updated ADA, ACC Measurement and Treatment Guidelines for High Risk Patients
5. AMDL Receives a Significant Updated Appraisal of Its JJB China Production Facilities
6. Biopure Launches Updated Website
7. SleepQuest Launches Updated Web Site
8. Updated Drug Development Scrip Report Responds to the Pharma Industrys Major Changes
9. Updated NIH Guidelines Offer Valuable Information on Asthma Diagnosis and Management
10. CEL-SCI Takes Delivery of New Manufacturing Facility
11. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... Scientists at the University of Athens ... for mesothelioma may be hampering the research that could lead to one good one. ... to read it now. , The team evaluated 98 mesothelioma patients ...
(Date:5/25/2016)... Connecticut (PRWEB) , ... May 25, 2016 , ... ... the U.S. Food and Drug Administration (FDA) has granted the company’s orphan drug ... the company’s second orphan drug designation granted by the FDA. , Spinocerebellar ...
(Date:5/24/2016)... La Jolla, CA (PRWEB) , ... May 24, 2016 , ... ... and financial planning for corporate executives and entrepreneurs, held The Future of San Diego ... leaders in the San Diego life science community attended the event with speakers Dr. ...
(Date:5/23/2016)... ... May 23, 2016 , ... PrecisionAg® Media has ... 2017 and Beyond. The paper outlines the key trends that are creating both ... “We’ve witnessed a lot of highs and lows as the precision agriculture market ...
Breaking Biology Technology:
(Date:3/21/2016)... -- Unique technology combines v ...   Xura, Inc. (NASDAQ: ... communications services, today announced it is working alongside SpeechPro ... particularly those in the Financial Services Sector, the ability ... a mobile app, alongside, and in combination with, traditional ...
(Date:3/15/2016)... -- Yissum Research Development Company of the Hebrew ... Hebrew University, announced today the formation of Neteera ... human biological indicators. Neteera Technologies has completed its first ... ... emissions from sweat ducts, enables reliable and speedy biometric ...
(Date:3/11/2016)... -- --> --> ... Market by Technology (Pattern Recognition), by Component (Hardware, Software, ... (On-Premises and Cloud), by Industry Vertical and by Region ... global market is expected to grow from USD 12.49 ... at a CAGR of 19.1%. , ...
Breaking Biology News(10 mins):